CLRB

Business Context and Reporting Period

Company: Novelos Therapeutics, Inc. (Note: Metadata listed "Cellectar Biosciences," but the filing text identifies the registrant as Novelos Therapeutics, Inc.)
Reporting Period: Quarter and nine months ended September 30, 2009.
Business Overview: Novelos is a biopharmaceutical company developing oxidized glutathione-based compounds for cancer and hepatitis. Its lead compound, NOV-002, is in Phase 3 clinical trials for non-small cell lung cancer (NSCLC). The company has incurred operating losses since inception and relies on equity financing and collaboration agreements to fund operations.

Key Financial Metrics

Note: The company reported a significant non-cash "Loss on derivatives" of $446,685 for the quarter and $2,830,274 for the nine months, driven by changes in the fair value of warrants with "down-round" provisions.

Material Changes vs. Prior Period

• Revenue: Decreased to $13,702 (Q3 2009) from $35,513 (Q3 2008) and $76,983 (9M 2009) from $89,523 (9M 2008). Revenue consists primarily of amortized license fees and government grants.
• Operating Expenses:
  • R&D: Decreased 10% in Q3 and 60% in the nine-month period compared to 2008. This reduction is attributed to the completion of patient enrollment in the Phase 3 trial in March 2008, leading to lower clinical costs.
  • G&A: Decreased 12% in Q3 and 24% (adjusted for a one-time credit in 2008) in the nine-month period due to cost-cutting measures.
• Liquidity: Cash and equivalents increased significantly from $1,262,452 at year-end 2008 to $5,567,114 at September 30, 2009, driven by financing activities.
• Capital Structure: The company issued Series E Preferred Stock and common stock to Purdue Pharma L.P. and exchanged Series D Preferred Stock for Series E. This resulted in a new derivative liability of approximately $2.1 million.

Outlook, Risks, and Management Commentary

• Phase 3 Trial Status: The primary endpoint for the NOV-002 NSCLC trial is increased median overall survival, requiring 725 events (deaths). Results are anticipated in early 2010.
• Liquidity and Runway: Management believes current cash plus proceeds from the final closing of the August 2009 Purchase Agreement with Purdue (completed November 10, 2009, for $5.5 million) will fund operations into the third quarter of 2010.
• Going Concern Risk: The company's ability to continue as a going concern beyond Q3 2010 is dependent on the favorable results of the Phase 3 trial and the ability to secure additional funding. Unfavorable results could force a scale-back of operations or cessation.
• Collaboration Agreements:
  • Mundipharma: Exclusive license for Europe, Asia (excluding China), and Australia. Includes potential launch payments up to $25 million and sales-based payments up to $60 million.
  • Lee's Pharmaceutical: Exclusive license for the Chinese Territory.
• Restrictions: Holders of Series E Preferred Stock have significant control rights, prohibiting the company from paying common dividends, issuing equity below $0.65, or incurring debt over $500,000 without consent.

Key Facts for Investor Verification

• Phase 3 Trial Outcome: Verify the timeline and preliminary data for the NOV-002 NSCLC trial, as this is the primary determinant of future funding and valuation.
• Derivative Liability Volatility: Monitor the fair value of outstanding warrants with "down-round" provisions, as fluctuations in stock price directly impact reported net loss.
• Preferred Stock Dividends: Note the $2.4 million in accrued but unpaid preferred dividends and the potential for further dilution if paid in stock.
• Capital Requirements: Confirm the company's ability to raise capital post-Q3 2010, given the "substantial doubt" regarding going concern status noted in the prior year's audit.
• Purdue Pharma Relationship: Verify the terms of the exclusive negotiation period and right of first refusal granted to Purdue for U.S. rights to NOV-002.